Low Concentration of Lipoprotein(a) is an Independent Predictor of
                    Incident Type 2 Diabetes

Wenhao Liu; Guanzhao Zhang; Zifan Nie; Xiangfeng Guan; Tingting Sun; Xiaodong Jin; Bo Li

doi:10.1055/a-2316-9124

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2024; 56(07): 504-508
DOI: 10.1055/a-2316-9124

Original Article: Endocrine Care

Low Concentration of Lipoprotein(a) is an Independent Predictor of Incident Type 2 Diabetes

Wenhao Liu

¹Cardiology, Zibo Central Hospital, Zibo, China (Ringgold ID: RIN117906)

,

Guanzhao Zhang

¹Cardiology, Zibo Central Hospital, Zibo, China (Ringgold ID: RIN117906)

,

Zifan Nie

¹Cardiology, Zibo Central Hospital, Zibo, China (Ringgold ID: RIN117906)

,

Xiangfeng Guan

²Cardiology, Shandong Second Medical University, Weifang, China (Ringgold ID: RIN372527)

,

Tingting Sun

²Cardiology, Shandong Second Medical University, Weifang, China (Ringgold ID: RIN372527)

,

Xiaodong Jin

³Geriatric Medicine, Zibo Central Hospital, Zibo, China (Ringgold ID: RIN117906)

,

Bo Li

¹Cardiology, Zibo Central Hospital, Zibo, China (Ringgold ID: RIN117906)

› Author Affiliations

Abstract

The aim of the study was to assess the association between lipoprotein(a) [Lp(a)] concentration and incident type 2 diabetes. A meta-analysis of qualified studies on the relationship of low levels of Lp(a) concentration with incident type 2 diabetes was conducted. PubMed and Cochrane libraries were searched for randomized controlled trials containing data on events. Seven randomized trials with 227178 subjects were included in this analysis. We found an inverse association of the levels of Lp(a) concentration with risk of type 2 diabetes with approximately 37% lower relative risk in the group with the highest concentration compared with group with the lowest concentration. The current available evidence from prospective studies suggests that there is an inverse association between the levels of Lp(a) concentration and risk of type 2 diabetes, with a higher risk of type 2 diabetes at low levels of Lp(a) concentration. Therefore, we believe that the low levels of Lp(a) concentration is an independent predictor of incident type 2 diabetes.

Keywords

lipoprotein(a) - meta-analysis - inverse association - type 2 diabetes

Full Text

References

References
1 Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 2017; 69: 692-711
2 Larsson SC, Wang L, Li X. et al. Circulating lipoprotein(a) levels and health outcomes: Phenome-wide Mendelian randomization and disease-trajectory analyses. Metabolism 2022; 137: 155347
3 El Sayed NA, Aleppo G, Aroda VR. et al. 2. Classification and diagnosis of diabetes: standards of care in diabetes-2023 [published correction appeared in Diabetes Care 2023 Feb 01] [published correction appeared in Diabetes Care 2023; Sep 1; 46: 1715]. Diabetes Care 2023; 46: S19-S40
4 Erqou S, Thompson A, Di Angelantonio E. et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010; 55: 2160-2167
5 Kamstrup PR, Tybjaerg-Hansen A, Steffensen R. et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301: 2331-2339
6 Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082-1085
7 Kronenberg F. Human genetics and the causal role of lipoprotein(a) for various diseases. Cardiovasc Drugs Ther 2016; 30: 87-100
8 Paige E, Masconi KL, Tsimikas S. et al. Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol 2017; 16: 38
9 Higgins JP, Altman DG, Gøtzsche PC. et al. The Cochrane ollaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928
10 Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1-30
11 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
12 Gudbjartsson DF, Thorgeirsson G, Sulem P. et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol 2019; 74: 2982-2994
13 Ye Z, Haycock PC, Gurdasani D. et al. The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?. Diabetes 2014; 63: 332-342
14 Mora S, Kamstrup PR, Rifai N. et al. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem 2010; 56: 1252-1260
15 Muhanhali D, Zhai T, Cai Z. et al. Lipoprotein(a) concentration is associated with risk of type 2 diabetes and cardiovascular events in a Chinese population with very high cardiovascular risk. Endocrine 2020; 69: 63-72
16 Schwartz GG, Szarek M, Bittner VA. et al. Relation of lipoprotein(a) levels to incident type 2 diabetes and modification by alirocumab treatment. Diabetes Care 2021; 44: 1219-1227
17 Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol 2013; 1: 220-227
18 Skoumas I, Andrikou I, Grigoriou K. et al. Lipoprotein(a), metabolic profile and new-onset type 2 diabetes in patients with familial combined hyperlipidemia: a 9 year follow-up study. J Clin Lipidol 2023; 17: 512-518
19 Boras J, Ljubic S, Car N. et al. Lipoprotein(a) predicts progression of carotid artery intima-media thickening in patients with type 2 diabetes: a four-year follow-up. Wien Klin Wochenschr 2010; 122: 159-164
20 Wakabayashi I, Masuda H. Lipoprotein (a) as a determinant of arterial stiffness in elderly patients with type 2 diabetes mellitus. Clin Chim Acta 2006; 373: 127-131
21 Real JT, Folgado J, Molina MM. et al. Homocisteina plasmática, Lp(a) y marcadores de estrés oxidativo en la vasculopatía periférica del paciente con diabetes tipo 2. Clin Invest Arterioscler 2016; 28: 188-194
22 Gazzaruso C, Coppola A, Montalcini T. et al. Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus. Endocrine 2012; 41: 89-95
23 Yun JS, Lim TS, Cha SA. et al. Lipoprotein(a) predicts the development of diabetic retinopathy in people with type 2 diabetes mellitus. J Clin Lipidol 2016; 10: 426-433
24 Ren X, Zhang Z, Yan Z. Association between lipoprotein (A) and diabetic nephropathy in patients with type 2 diabetes mellitus: a meta-analysis. Front Endocrinol (Lausanne) 2021; 12: 633529
25 Meroni M, Longo M, Lombardi R. et al. Low lipoprotein(a) levels predict hepatic fibrosis in patients with nonalcoholic fatty liver disease. Hepatol Commun 2022; 6: 535-549
26 Tolbus A, Mortensen MB, Nielsen SF. et al. Kringle IV type 2, not low lipoprotein(a), as a cause of diabetes: a novel genetic approach using SNPs associated selectively with lipoprotein(a) concentrations or with Kringle IV type 2 repeats. Clin Chem 2017; 63: 1866-1876
27 Emdin CA, Khera AV, Natarajan P. et al. Phenotypic characterization of genetically lowered human lipoprotein(a) levels. J Am Coll Cardiol 2016; 68: 2761-2772
28 Buchmann N, Scholz M, Lill CM. et al. Association between lipoprotein(a) level and type 2 diabetes: no evidence for a causal role of lipoprotein(a) and insulin. Acta Diabetol 2017; 54: 1031-1038